首頁 > 市場調查報告書 > 製藥

以基因為基之藥物開發

市場調查報告書

商品編碼

1544731

細胞株開發市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Cell Line Development Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年07月10日 | 出版商:

Global Market Insights Inc. | 英文 218 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

在產品發布和技術創新激增的推動下，細胞株開發市場預計 2024 年至 2032 年複合年成長率將達到 10.3%。

生技公司和研究人員正在利用 CRISPR 基因編輯、自動化和高通量篩選等尖端技術，旨在打造高效可靠的細胞系。這些技術進步不僅加速了細胞系的開發，也提高了細胞系在藥物發現、治療生產和生物醫學研究等多種應用中的精確度。例如，2023 年 6 月，JSR Life Sciences 旗下的 KBI Biopharma 推出了 KBI PURE 平台。這種創新的微生物細胞株開發平台有望提高微生物表現效率，特別是對於生物製藥生產。

整個市場分為產品和服務、來源、細胞株、應用、最終用途和地區。

就來源而言，在生物製藥生產需求不斷成長的推動下，細胞株開發市場中的哺乳動物細分市場將在 2032 年顯著成長。研究人員依靠哺乳動物細胞，同時採用基因工程技術來提高生產力和穩定性，從而產生重要的治療性蛋白質和抗體。此外，隨著這些進步，哺乳動物細胞係正在產生高品質的治療方法，滿足對複雜醫療日益成長的需求。

從應用來看，藥物發現領域的細胞株開發產業價值預計將在 2024 年至 2032 年期間上升。透過建構模擬人類生理學的專門細胞系，科學家們對藥物交互作用和作用有了更深入的了解。細胞株開發的不斷完善為更準確的藥物測試鋪平了道路，最終加速了新藥物的發現。

從地區來看，在再生醫學日益受到關注的推動下，亞太地區細胞株開發市場規模預計將在 2024 年至 2032 年間呈現強勁成長。研究人員和生物技術公司正在利用先進的細胞株技術來開發修復或替換受損組織和器官的療法。細胞株開發的持續發展也將支持再生醫學的進步，為治療該地區的各種醫療狀況帶來新的希望。

產業生態系統分析
產業影響力
- 成長動力
  - 全球疫苗產量不斷成長
  - 全球癌症盛行率不斷上升
  - 細胞株開發的技術創新
  - 不斷發展的生物技術產業
- 產業陷阱與挑戰
  - 複雜的監管環境
  - 幹細胞研究相關問題
成長潛力分析
未來市場趨勢
監管環境
波特的分析
PESTEL分析

第 4 章：競爭格局

介紹
公司市佔率分析
公司矩陣分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產品和服務分類，2021 - 2032 年

主要趨勢
試劑和介質
裝置
- 孵化器
- 離心機
- 生物反應器
- 倉儲設備
- 顯微鏡
- 電穿孔器
- 螢光活化細胞分選
- 其他設備
配件及消耗品
服務

第 6 章：市場估計與預測：按來源分類，2021 - 2032 年

主要趨勢
哺乳動物
非哺乳動物
- 昆蟲
- 兩棲類

第 7 章：市場估計與預測：按細胞株，2021 - 2032

主要趨勢
重組
雜交瘤
連續性細胞系
原代細胞系

第 8 章：市場估計與預測：按應用分類，2021 - 2032

主要趨勢
生物生產
藥物發現
毒性測試
組織工程
研究應用

第 9 章：市場估計與預測：按最終用途，2021 - 2032 年

主要趨勢
製藥和生物技術公司
學術及研究機構
合約研究組織 (CRO)

第 10 章：市場估計與預測：按地區，2021 - 2032

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 11 章：公司簡介

Advanced Instruments, LLC
Aragen Life Sciences Ltd.
ASIMOV
Cytiva (Danaher Corporation)
Eurofins Scientific
Fyonibio
GenScript Biotech
Lonza Group AG
Novartis AG
ProBioGen
PromoCell
Sartorius AG
Sigma Aldrich (Merck KGaA)
Thermo Fisher Scientific Inc.
WuXi AppTec

簡介目錄

Product Code: 429

Cell Line Development Market is projected to record a 10.3% CAGR from 2024 to 2032, driven by a surge in product launches and technological innovations.

Biotech firms and researchers are harnessing cutting-edge techniques like CRISPR gene editing, automation, and high-throughput screening, aiming to craft cell lines that are both efficient and reliable. These technological strides are not only accelerating the development of cell lines but also bolstering their precision for diverse applications, spanning drug discovery, therapeutic production, and biomedical research. For example, in June 2023, KBI Biopharma, under the umbrella of JSR Life Sciences, unveiled the KBI PURE platform. This innovative microbial cell line development platform is poised to enhance microbial expression efficiencies, especially for biopharmaceutical production.

The overall market is segregated into products and services, source, cell line, application, end-use, and region.

In terms of source, the mammalian segment in the cell line development market will experience significant growth by 2032 driven by an escalating demand in biopharmaceutical production. Researchers are counting on mammalian cells while employing genetic engineering techniques to boost productivity and stability, thereby producing vital therapeutic proteins and antibodies. Moreover, with these advancements, mammalian-derived cell lines are generating high-quality therapeutics, catering to the rising appetite for sophisticated medical treatments.

By application, the cell line development industry value from the drug discovery segment is projected to rise from 2024 to 2032. This can be attributed to the escalating need for precise and efficient therapeutic testing models. By crafting specialized cell lines that emulate human physiology, scientists are gaining deeper insights into drug interactions and effects. This ongoing refinement in cell line development is paving the way for more accurate drug testing, ultimately expediting the discovery of new medications.

Regionally, the Asia Pacific cell line development market size is projected to exhibit robust growth between 2024 and 2032, fueled by the growing focus on regenerative medicine. Researchers and biotech companies are leveraging advanced cell line technologies to develop therapies for repairing or replacing damaged tissues and organs. The ongoing evolution in cell line development will also support the advancement of regenerative medicine to offer new hope for treating a wide range of medical conditions across the region.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing vaccine production worldwide
  - 3.2.1.2 Increasing prevalence of cancer across globe
  - 3.2.1.3 Technological innovation in cell line development
  - 3.2.1.4 Growing biotechnology industry
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Complex regulatory landscape
  - 3.2.2.2 Issues related to stem cell research
3.3 Growth potential analysis
3.4 Future market trends
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Products and Services, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Reagents and media
5.3 Equipment
- 5.3.1 Incubator
- 5.3.2 Centrifuges
- 5.3.3 Bioreactors
- 5.3.4 Storage equipment
- 5.3.5 Microscopes
- 5.3.6 Electroporators
- 5.3.7 Fluorescence-activated cell sorting
- 5.3.8 Other equipment
5.4 Accessories and consumables
5.5 Services

Chapter 6 Market Estimates and Forecast, By Source, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Mammalian
6.3 Non-mammalian
- 6.3.1 Insects
- 6.3.2 Amphibians

Chapter 7 Market Estimates and Forecast, By Cell Line, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Recombinant
7.3 Hybridomas
7.4 Continuous cell lines
7.5 Primary cell lines

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 Bioproduction
8.3 Drug discovery
8.4 Toxicity testing
8.5 Tissue engineering
8.6 Research applications

Chapter 9 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

9.1 Key trends
9.2 Pharmaceutical and biotechnology companies
9.3 Academic and research institutes
9.4 Contract research organizations (CROs)

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 The Netherlands
- 10.3.7 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Rest of Asia Pacific
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE
- 10.6.4 Rest of Middle East and Africa